BioWorld

Feb. 9, 2006

View Archived Issues

Entereg’s Positive Phase III Data Drive Up Adolor’s Stock

Adolor Corp. unveiled positive Phase III data on Entereg (alvimopan), its partnered product for postoperative ileus, boosting shares in the company. (BioWorld Today) Read More

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Read More

PDZ Binding Domain Origins Determinant Of Flu Severity

Read More

Optimized Proteases Garner $30M In Catalyst’s Series B

Read More

Oscient Gets Ramoplanin Rights Back From Pfizer

Read More

Clinic Roundup

Read More

Other News To Note

Read More